Beta

Scholar rock holding corporationSRRK.US Overview

US StockHealthcare
(No presentation for SRRK)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

SRRK AI Insights

SRRK Overall Performance

SRRK AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SRRK Recent Performance

0.95%

Scholar rock holding corporation

-1.10%

Avg of Sector

-0.49%

S&P500

SRRK PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check SRRK's Trend

SRRK Key Information

SRRK Valuation Metrics

SRRK Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Price of SRRK

SRRK FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.29
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
13.14
PB Ratio
23.07
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.29
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
13.14
PB Ratio
23.07
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is SRRK's latest earnings report released?

    The most recent financial report for Scholar rock holding corporation (SRRK) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SRRK's short-term business performance and financial health. For the latest updates on SRRK's earnings releases, visit this page regularly.

  • How much debt does SRRK have?

    As of the end of the reporting period, Scholar rock holding corporation (SRRK) had total debt of 108.92M, with a debt ratio of 0.27. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does SRRK have?

    At the end of the period, Scholar rock holding corporation (SRRK) held Total Cash and Cash Equivalents of 327.33M, accounting for 0.81 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is SRRK's EPS continuing to grow?

    According to the past four quarterly reports, Scholar rock holding corporation (SRRK)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.75. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of SRRK?

    Scholar rock holding corporation (SRRK)'s Free Cash Flow (FCF) for the period is -75.53M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 52.47% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of SRRK?

    The latest valuation data shows Scholar rock holding corporation (SRRK) has a Price-To-Earnings (PE) ratio of -13.47 and a Price/Earnings-To-Growth (PEG) ratio of 0.78. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.

SRRK Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1